Probiotics can improve the clinical outcomes of hepatic encephalopathy: An update meta-analysis

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue 6, 2015, Pages 674-682

  Zhao, Li Na ^a   Yu, Tao ^b   Lan, Shao Yang ^a   Hou, Jiang Tao ^a   Zhang, Zheng Zheng ^a   Wang, Shuang Shuang ^a   Liu, Feng Bin ^a  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; PROBIOTIC AGENT;

ADVERSE OUTCOME; ARTICLE; BACILLUS; BACILLUS MESENTRICUS; BIFIDOBACTERIACEAE; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM INFANTIS; BIFIDOBACTERIUM LONGUM; CLOSTRIDIUM BUTYRICUM; DRUG EFFICACY; EMERGENCY WARD; ENTEROCOCCUS FAECALIS; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; INFECTION; LACTIC ACID BACTERIUM; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LEUCONOSTOC MESENTEROIDES; META ANALYSIS; PEDIACOCCUS PENTOSECEUS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SICKNESS IMPACT PROFILE; THERMOPHILE; TREATMENT OUTCOME;

HEPATIC ENCEPHALOPATHY; HUMANS; PROBIOTICS; TREATMENT OUTCOME;

EID: 84949315143     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.03.008     Document Type: Article

References (37)

1. Stepanova M., Mishra A., Venkatesan C., Younossi Z.M. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 2012, 10:1034-1041.
2. Bajaj J.S. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008, 14:3609-3615.
3. Leise M.D., Poterucha J.J., Kamath P.S., Kim W.R. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc 2014, 89:241-253.
4. Bajaj J.S. The role of microbiota in hepatic encephalopathy. Gut Microbes 2014, 5:397-403.
5. McGee R.G., Bakens A., Wiley K., Riordan S.M., Webster A.C. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2011, 11:CD008716.
6. Shukla S., Shukla A., Mehboob S., Guha S. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther 2011, 33:662-671.
7. Holte K., Krag A., Gluud L.L. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res 2012, 42:1008-1015.
8. Mohammad R.A., Regal R.E., Alaniz C. Combination therapy for the treatment and prevention of hepatic encephalopathy. Ann Pharmacother 2012, 46:1559-1563.
9. Liu Q., Duan Z.P., Ha D.K., Bengmark S., Kurtovic J., Riordan S.M. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39:1441-1449.
10. Bajaj J.S., Saeian K., Christensen K.M., Hafeezullah M., Varma R.R., Franco J., et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008, 103:1707-1715.
11. Sharma P., Sharma B.C., Puri V., Sarin S.K. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008, 20:506-511.
12. Mittal V.V., Sharma B.C., Sharma P., Sarin S.K. A randomized controlled trial comparing lactulose, probiotics, and l-ornithine l-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2011, 23:725-732.
13. Saji S., Kumar S., Thomas V. A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Trop Gastroenterol 2011, 32:128-132.
14. Agrawal A., Sharma B.C., Sharma P., Sarin S.K. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012, 107:1043-1050.
15. Zhao X.H., Feng Q., Zhanf J., Jiang Y.F. [A randomized-controlled trial to compare the effect of lactulose and probiotics on treatment of minimal hepatic encephalopathy]. Pract J Clin Med 2013, 10:61-63.
16. Bajaj J.S., Heuman D.M., Hylemon P.B., Sanyal A.J., Puri P., Sterling R.K., et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014, 39:1113-1125.
17. Sharma K., Pant S., Misra S., Dwivedi M., Misra A., Narang S., et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi J Gastroenterol 2014, 20:225-232.
18. Malaguarnera M., Greco F., Barone G., Gargante M.P., Malaguarnera M., Toscano M.A. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007, 52:3259-3265.
19. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999, 354:1896-1900.
20. Malaguarnera M., Gargante M.P., Malaguarnera G., Salmeri M., Mastrojeni S., Rampello L., et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010, 22:199-206.
21. Yang L.L., Zou B., Wang J., Du Y., He M., Guan X.Q. [Observation on the efficacy of lactulose and probiotics in preventing hepatic encephalopathy]. China Medical Herald 2011, 8:75-76.
22. Shen Z., Ma L., Zhang W.H., Gao S.P. [Curative effect observation of Lactobacillus acidophilus complex combined fiberform in treatment of hepatic encephalopathy]. Chin J Microecol 2013, 25:679-681.
23. Pereg D., Kotliroff A., Gadoth N., Hadary R., Lishner M., Kitay-Cohen Y. Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition 2011, 27:177-181.
24. Lunia M.K., Sharma B.C., Sharma P., Sachdeva S., Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 2014, 12:1003-1008.
25. Loguercio C., Del Vecchio Blanco C., Coltorti M. Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res 1987, 15:335-343.
26. Shu M., Che Y.G. [Curative effects of bacillus licheniform is capsule on course of subclinical hepatic encephalopathy]. Chin J Gen Pract 2008, 16:1119-1120.
27. Lata J., Juránková J., Príbramská V., Fric P., Senkyrík M., Díte P., et al. [Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonisation, endo-toxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis]. Vnitr Lek 2006, 52:215-219.
28. Ye R.H., Ye Z., Ruan B. [Effect of administration of bifid triple viable on endo-toxemia, ammonia concentrarion, and number connection test in patients with liver cirrhosis]. Chin J Microecol 2006, 18:245-246.
29. Liu J.S., Tian Y., Fu J., Zhang X.H., Liu J., Lin J. [Effects of probiotics agents treatment on the course of subclincal hepatic encephalopathy]. Chin J Postgrad Med 2006, 29:12-14.
30. Zhang S.Q., Liu C.X., Ye X.X., Ye W.J., Wang X.K. [Effects of the regulation by intestinal probiotics and fermantative microflora on the subclinical hepatic encephalopathy of the patients with hepatocirrhosis]. J Med Res 2007, 36:48-50.
31. Qiao X.L. [Clinical researches of bifid triple viable on the treatment of subclinical hepatic encephalopathy]. Chin J Clin Gastroenterol 2010, 2:105-106.
32. Liu W.Z. [Effect of administration of Medilac-S probiotics on endo-toxemia and hepatic encephalopathy]. Chin Med Factory Mine 2009, 22:296-297.
33. Wang X.Y., Qu C.M., Liang S.W., Cao Y.J., Li L.Y., Zhong C.Q., et al. [Efficacy analysis on treatment of subclinical hepatic encephalopathy by live combined Bacillus subtilis and Enterococcus faecium enteric-coated capsules]. Prog Modern Biomed 2012, 12:6489-6491.
34. Wein C., Koch H., Popp B., Oehler G., Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004, 39:739-745.
35. Bajaj J.S., Saeian K., Schubert C.M., Hafeezullah M., Franco J., Varma R.R., et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009, 50:1175-1183.
36. Schomerus H., Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001, 16:37-41.
37. Cordoba J., Ventura-Cots M., Simón-Talero M., Amorós À., Pavesi M., Vilstrup H., et al. CANONIC Study Investigators of EASL-CLIF Consortium. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol 2014, 60:275-281.